Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study

Long-term survival in amyotrophic lateral sclerosis: A population-based study

(2014) Elisabetta Pupillo et al.   ANNALS OF NEUROLOGY

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

(2013) Merit E Cudkowicz et al.   LANCET NEUROLOGY

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS

(2013) Ettore Beghi et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis

(2012) Luc Dupuis et al.   PLoS One

Treating patients with schizophrenia deficit with erythropoietin?

(2012) Guillaume Fond et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Organ-Protective and Immunomodulatory Effects of Erythropoietin - An Update on Recent Clinical Trials

(2011) Christoffer Sølling   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study

(2011) Adriano Chiò et al.   MUSCLE & NERVE

ALS clinical trials: Do enrolled patients accurately represent the ALS population?

(2011) A. Chio et al.   NEUROLOGY

Recombinant human erythropoietin reduces aggregation of mutant Cu/Zn-binding superoxide dismutase (SOD1) in NSC-34 cells

(2011) Goang-Won Cho et al.   NEUROSCIENCE LETTERS

A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis

(2010) Mamede de Carvalho et al.   Amyotrophic Lateral Sclerosis

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

(2010) Swati P Aggarwal et al.   LANCET NEUROLOGY

Erythropoietin in amyotrophic lateral sclerosis: A pilot, randomized, double-blind, placebo-controlled study of safety and tolerability

(2009) Giuseppe Lauria et al.   Amyotrophic Lateral Sclerosis

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial

(2009) Vincent Meininger et al.   Amyotrophic Lateral Sclerosis

Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis

(2009) P. Janik et al.   JOURNAL OF NEURAL TRANSMISSION

Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons

(2009) P. E. Sanchez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)

(2009) Gregory Haljan et al.   STROKE

Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues

(2007) G Logroscino et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY